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Abstract
Omeprazole is a proton pump inhibition and ranitidine is an H2 histamine receptor antagonist widely used in the treatment of 
gastroesophageal reflex disease, peptic ulcer disease, Zollinger-Ellison syndrome and as a protector of the gastric mucosae. We 
report a case of occupational contact allergy to omeprazole and ranitidine. A 48-year-old man, with no pre-existing history of 
atopy or lifestyle factors. He neither had any medical history of consumption of drugs such as ranitidine and omeprazole. He 
worked for 19 months in the pharmaceutical company that manufactured ranitidine base. He presented rash in the face and 
eczema on the dorsum of the hands with itching. The study by prick tests with ranitidine gave negative response. Patch testing 
with ranitidine base and ranitidine hydrochloride gave positive response. A month later, when the patient was asymptomatic he 
returned to the pharmaceutical company, being switched from this previous job to the reactor manufacturing omeprazole. A few 
days after that, he presented with erythematous eruptions involving face and neck with itching. Prick tests, path tests and in vitro 
laboratories studies with omeprazole gave positives. In this case the patient presented hypersensitivity type I at omeprazole and 
hypersensitivity type IV at omeprazole and ranitidine. Our aportation indicates the importance of careful analysis of the occupa-
tional exposure histories of patients with the suspected type I or type IV hypersensitivity to allergens, to determine whether work 
exposure is the cause. Med Pr 2017;68(3)
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OCCUPATIONAL CONTACT ALLERGY TO OMEPRAZOLE AND RANITIDINE
CASE REPORT
INTRODUCTION
Occupational exposure to active pharmaceutical in-
gredients may cause adverse health effects [1]. Althou-
gh omeprazole is potentially sensitizing, occupatio-
nally acquired cases in pharmaceutical industry are 
rare [2–6]. 
We report one case of occupational contact allergy 
to omeprazole and ranitidine.
CASE REPORT
A  48-year-old man, with no pre-existing history of 
atopy or lifestyle risk factors. Neither did he have any 
medical history of consumption of drugs such as ra-
nitidine and omeprazole. He worked for 19 months in 
the synthesis of active ingredients for a pharmaceutical 
company that manufactured ranitidine base. He pre-
sented rash in the face and eczema on the dorsum of 
the hands with itching. Skin symptoms were triggered 
in the first 4–6 h of starting the workday, and required 
treatment with corticosteroid topical and anti-histami-
ne oral for resolution. The patient did not develop skin 
reactions in periods without work activity (weekends 
and holiday periods).
Prick tests with ranitidine were performed at 30 mg/ 
ml and 3 mg/ml, and gave negative response.
Patch testing was done according to the  GEIDC 
(Grupo Español de Investigación de Dermatitis de 
Contacto  – the Spanish Contact Dermatitis Research 
Group) standard series and patch testing – with rani-
tidine base (5% pet), ranitidine hydrochloride (1% pet) 
and ranitidine hydrochloride  (5%  pet). Results were 
read at 48 h (day 2) and 96 h (day 4), which are descri-
bed in the Table 1. Prick tests and path tests gave nega-
tive results in all 10 healthy controls.
A  month later, when the patient was asymptoma-
tic, he returned to the pharmaceutical company, being 
switched from his previous job to the reactor manufac-
turing omeprazole. A few days after that, he presented 
with erythematous eruptions involving face and neck 
with itching.
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Prick tests with omeprazole were performed at 
concentration of  20  mg/ml and the time of reading 
was 12 min, obtaining a positive result: papule 6×8 mm, 
suggesting immediate-type allergy.
In vitro laboratory studies, consisting of a histamine 
release test by radioimmunoassay, were also performed 
to support the results obtained through prick testing: 
this test showed positive results with omeprazole, with 
a  percentage rate of histamine release of  42% (cut-off 
value in the test: 30%). 
Omeprazole was patch-tested in saline solution at 
0.1%,  0.5% and  1%. Results were read at  48  h  (day 2) 
and 96 h (day 4), and are described in the Table 1. Prick 
tests and patch tests gave negative results in 10 healthy 
controls.
DISCUSSION
Omeprazole is a proton pump inhibitor. It is admini-
stered orally or intravenously, and is widely used in the 
treatment of gastroesophageal reflex disease, peptic ul-
cer disease, and Zollinger-Ellison syndrome. 
Ghatan et al. (2014) [7] provides a study of 96 wor-
kers exposed to omeprazole during manufacturing pro-
cess for suspected allergy. Twenty-eight workers have 
positive patch tests. The results of prick tests were all ne-
gative. Confino-Cohen and Golberg (2006) [8] proposed 
a desensitization protocol for omeprazole anaphylaxis. 
Ranitidine is an H2 histamine receptor antagonist, 
used in the treatment of duodenal ulcers and gastric 
hypersecretory syndromes. Exposure to ranitidine 
compounds is an occupational hazard in the pharma-
ceutical industry and reactions during the drug manu-
facturing process have been described [9,10].
In this case the patient presented hypersensitivity 
type  I at omeprazole and hypersensitivity type  IV at 
omeprazole and ranitidine. Both omeprazole and rani-
tidine are low molecular weight substances (354.42 Da 
and 350.9 Da, respectively), and may therefore trigger 
allergic pathology mediated by a  type  I  hypersensiti-
vity mechanism. This patient developed type  IV hy-
persensitivity against both omeprazole and ranitidine, 
but also type I against omeprazole, which support the 
relevance of low molecular weight allergens in the de-
velopment of allergic disease by different mechanisms.
CONCLUSIONS
We cannot conclude whether the sensitization to rani-
tidine and omeprazole in the case of this patient is due 
to a cross-sensitivity or a co-sensitivity, since no in vitro 
studies have been carried out by immunoblotting. 
Our aportation indicates the importance of careful 
analysis of the occupational exposure histories of pa-
tients with suspected type I or type IV hypersensitivity 
to allergens, in order to determine whether work expo-
sure is the actual cause.
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GEIDC standards series patch – –
GEIDC – Grupo Español de Investigación de Dermatitis de Contacto (the Spanish 
Contact Dermatitis Research Group).
“–” – negative reaction, “+” – weak positive reaction, “++” – strong positive reaction, 
“+++” – extreme positive reaction.
Contact allergy to omeprazole and ranitidine 3Nr 3
26(6):287–90, https://doi.org/10.1097/DER.0000000000 
000139.
7. Ghatan PH, Marcusson-Stahl M, Matura  M, Björkhe-
den  C, Lundborg  P, Cederbrant  K. Sensitization to ome-
prazole in the occupational setting. Contact Dermatitis. 
2014(6);71:371–5, https://doi.org/10.1111/cod.12305.
8. Confino-Cohen R, Golberg A. Anaphylaxis to omeprazole 
diagnosis and desensitization protocol. Ann Allergy Asth-
ma Immunol. 2006;96(1):33–6, https://doi.org/10.1016/
S1081-1206(10)61037-X.
9. Romaguera C, Grimalt F, Vilaplana  J. Epidemic of occu- 
pational contact dermatitis from ranitidine. Contact Der- 
matitis. 1988;18(3):177–8, https://doi.org/10.1111/j.1600- 
0536.1988.tb04512.x. 
10. Ryan PJ, Rycroft RJ, Aston IR. Allergic contact dermatitis 
from occupational exposure to ranitidine hydrochloride. 
Contact Dermatitis. 2003;48(2):67–8, https://doi.org/10. 
1034/j.1600-0536.2003.480202.x.
This work is available in Open Access model and licensed under a Creative Commons Attribution-NonCommercial 3.0 Poland License / Ten utwór jest 
dostępny w modelu open access na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 3.0 Polska – http://creativecommons.org/
licenses/by-nc/3.0/pl/deed.en.
Publisher / Wydawca: Nofer Institute of Occupational Medicine, Łódź, Poland

